Corcept Therapeutics – a clinical-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic and neurologic disorders through modulation of the hormone cortisol – has reported positive late-stage results from its phase 3 trial evaluating relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ROSELLA trial demonstrated a progression-free survival (PFS) benefit in patients whose disease progressed during or after treatment with a PARP inhibitor (PARPi) – a population known to have particularly poor prognoses.
ROSELLA previously met its primary endpoint of improved PFS without requiring biomarker selection. Patients who received relacorilant, a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity, in combination with nab-paclitaxel chemotherapy achieved a statistically significant improvement in overall survival (OS) and a reduced risk of disease progression, resulting in enhanced patient outcomes.
At ESMO, Corcept also announced the expansion of its phase 2 BELLA study to include three new study arms. These will evaluate:
- Relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
- Relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARPi
- Relacorilant plus nab-paclitaxel in patients with endometrial cancer who have received one or two prior lines of therapy.
Bill Guyer, Corcept’s chief development officer, said: “The ROSELLA data give us confidence to expand the BELLA trial to include patients with ovarian cancer whose disease is platinum sensitive (an earlier stage of tumour progression), as well as patients with endometrial cancer.
“With the FDA’s recent acceptance of our New Drug Application for relacorilant in platinum-resistant ovarian cancer and the expansion of our BELLA trial, we are closer than ever to bringing new and vital treatment to patients in need.”